secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001558370-23-017778
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Q3 net revenue $74.6M (+27% QoQ); net loss narrows to $39.6M; LOQTORZI approved
--------------------------------------------------------------------------------

- Q3 2023 net revenue $74.6M, up 27% from Q2; net loss $39.6M ($0.41/sh) vs $86.7M ($1.11/sh) in Q3 2022.
- CIMERLI net sales $40.0M (+50% QoQ); UDENYCA net sales $33.0M (+4% QoQ); YUSIMRY launched with $1.4M Q3 sales.
- FDA approved LOQTORZI (toripalimab-tpzi) on Oct 27 for nasopharyngeal carcinoma; commercial launch expected Q1 2024.
- Closed Surface Oncology acquisition on Sep 8, adding clinical-stage anti-IL-27 and anti-CCR8 I-O pipeline assets.
- UDENYCA ONBODY BLA resubmitted Oct 4; potential approval late 2023 or early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837023017778/0001558370-23-017778-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837023017778/chrs-20231106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-017778

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer